Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Dova is a pharmaceutical company focused on acquiring, developing and commercializ...
Dova is a pharmaceutical company focused on acq...
RTI Surgical Holdings, Inc. is a leading global surgical implant company providing...
RTI Surgical Holdings, Inc. is a leading global...
Moderna is advancing messenger RNA (mRNA) science to create a new class of transfo...
Moderna is advancing messenger RNA (mRNA) scien...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedica...
Global Blood Therapeutics, Inc. (GBT) is a clin...
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...
Evelo Biosciences, Inc. is a clinical stage bio...
Join the National Investor Network and get the latest information with your interests in mind.